...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drug Design, Development and Therapy >Canagliflozin: a novel treatment option for type 2 diabetes
【24h】

Canagliflozin: a novel treatment option for type 2 diabetes

机译：Canagliflozin：2型糖尿病的新治疗选择

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: Type 2 diabetes continues to be a challenging disease to manage. The addition of new agents with a positive risk–benefit ratio could potentially assist clinicians and patients in achieving adequate diabetes control. Canagliflozin, the first sodium-glucose cotransporter 2 inhibitor presently available on the market, offers a unique mechanism of action: it inhibits renal reabsorption of glucose, thereby increasing urinary glucose excretion. It reduces hemoglobin A1c by approximately 0.37%–1.16%; it also reduces the patient's weight and systolic blood pressure and has a low risk for hypoglycemia. Adverse effects include an increased risk of urinary tract infections and genital mycotic infections. In this manuscript we review canagliflozin and its potential role in management of type 2 diabetes mellitus.
机译：摘要：2型糖尿病仍然是一种具有挑战性的疾病。风险收益比为正的新药的添加可能会帮助临床医生和患者实现适当的糖尿病控制。 Canagliflozin是目前市场上第一种钠-葡萄糖共转运蛋白2抑制剂，具有独特的作用机理：它抑制肾脏对葡萄糖的重吸收，从而增加尿中葡萄糖的排泄。它将血红蛋白A1c降低约0.37％–1.16％;它还可以减轻患者的体重和收缩压，降低低血糖的风险。不良反应包括尿路感染和生殖器真菌感染的风险增加。在本文中，我们回顾了卡格列净及其在2型糖尿病治疗中的潜在作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号